QQQ   423.39 (-0.58%)
AAPL   166.67 (-0.79%)
MSFT   406.63 (-1.27%)
META   504.11 (+2.01%)
GOOGL   156.53 (+0.68%)
AMZN   179.10 (-1.20%)
TSLA   149.80 (-3.63%)
NVDA   845.59 (+0.62%)
AMD   154.23 (+0.14%)
NIO   4.03 (+3.07%)
BABA   68.96 (+0.20%)
T   16.21 (+0.56%)
F   12.02 (-0.17%)
MU   112.99 (-2.87%)
GE   154.25 (-0.91%)
CGC   8.06 (+24.19%)
DIS   112.91 (-0.03%)
AMC   2.87 (-3.69%)
PFE   25.29 (-0.51%)
PYPL   62.22 (-1.64%)
XOM   118.40 (-0.19%)
QQQ   423.39 (-0.58%)
AAPL   166.67 (-0.79%)
MSFT   406.63 (-1.27%)
META   504.11 (+2.01%)
GOOGL   156.53 (+0.68%)
AMZN   179.10 (-1.20%)
TSLA   149.80 (-3.63%)
NVDA   845.59 (+0.62%)
AMD   154.23 (+0.14%)
NIO   4.03 (+3.07%)
BABA   68.96 (+0.20%)
T   16.21 (+0.56%)
F   12.02 (-0.17%)
MU   112.99 (-2.87%)
GE   154.25 (-0.91%)
CGC   8.06 (+24.19%)
DIS   112.91 (-0.03%)
AMC   2.87 (-3.69%)
PFE   25.29 (-0.51%)
PYPL   62.22 (-1.64%)
XOM   118.40 (-0.19%)
QQQ   423.39 (-0.58%)
AAPL   166.67 (-0.79%)
MSFT   406.63 (-1.27%)
META   504.11 (+2.01%)
GOOGL   156.53 (+0.68%)
AMZN   179.10 (-1.20%)
TSLA   149.80 (-3.63%)
NVDA   845.59 (+0.62%)
AMD   154.23 (+0.14%)
NIO   4.03 (+3.07%)
BABA   68.96 (+0.20%)
T   16.21 (+0.56%)
F   12.02 (-0.17%)
MU   112.99 (-2.87%)
GE   154.25 (-0.91%)
CGC   8.06 (+24.19%)
DIS   112.91 (-0.03%)
AMC   2.87 (-3.69%)
PFE   25.29 (-0.51%)
PYPL   62.22 (-1.64%)
XOM   118.40 (-0.19%)
QQQ   423.39 (-0.58%)
AAPL   166.67 (-0.79%)
MSFT   406.63 (-1.27%)
META   504.11 (+2.01%)
GOOGL   156.53 (+0.68%)
AMZN   179.10 (-1.20%)
TSLA   149.80 (-3.63%)
NVDA   845.59 (+0.62%)
AMD   154.23 (+0.14%)
NIO   4.03 (+3.07%)
BABA   68.96 (+0.20%)
T   16.21 (+0.56%)
F   12.02 (-0.17%)
MU   112.99 (-2.87%)
GE   154.25 (-0.91%)
CGC   8.06 (+24.19%)
DIS   112.91 (-0.03%)
AMC   2.87 (-3.69%)
PFE   25.29 (-0.51%)
PYPL   62.22 (-1.64%)
XOM   118.40 (-0.19%)
Free Trial
OTCMKTS:CLPBY

Coloplast A/S (CLPBY) Stock Price, News & Analysis

→ Emergency: Biden's $20 Trillion Mistake Could Cost YOU! (From GoldenCrest Metals) (Ad)
Free CLPBY Stock Alerts
$12.96
-0.11 (-0.84%)
(As of 04/17/2024 ET)
Compare
Today's Range
$12.87
▼
$13.04
50-Day Range
$11.80
▼
$14.30
52-Week Range
$9.90
▼
$14.77
Volume
50,478 shs
Average Volume
47,258 shs
Market Capitalization
N/A
P/E Ratio
39.27
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisAnalyst ForecastsChartDividendEarningsFinancialsHeadlinesSEC FilingsShort Interest
CLPBY stock logo

About Coloplast A/S Stock (OTCMKTS:CLPBY)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. The company was founded in 1954 and is headquartered in Humlebæk, Denmark.

CLPBY Stock Price History

CLPBY Stock News Headlines

April 18, 2024 | americanbankingnews.com
Contrasting Coloplast A/S (OTCMKTS:CLPBY) & Envoy Medical (NASDAQ:COCH)
March 1, 2024 | globenewswire.com
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
April 18, 2024 | GoldenCrest Metals (Ad)
Emergency: Biden's $20 Trillion Mistake Could Cost YOU!
The stakes have never been higher for your savings. Here's the hard truth: A banking crisis is looming. Your money is in the crosshairs of a $20 trillion commercial loan debt disaster, set to erupt.
February 28, 2024 | globenewswire.com
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
February 23, 2024 | finance.yahoo.com
Coloplast A/S (CLPBY)
February 12, 2024 | finance.yahoo.com
Coloplast A/S: Coloplast Earnings: Underlying Demand Remains Strong, but Medicare Fraudsters Could Hurt U.S. Growth
February 9, 2024 | finance.yahoo.com
Coloplast A/S - Allocation of Share Options
February 9, 2024 | globenewswire.com
Coloplast A/S - Allocation of Share Options
April 18, 2024 | GoldenCrest Metals (Ad)
Emergency: Biden's $20 Trillion Mistake Could Cost YOU!
The stakes have never been higher for your savings. Here's the hard truth: A banking crisis is looming. Your money is in the crosshairs of a $20 trillion commercial loan debt disaster, set to erupt.
February 9, 2024 | finance.yahoo.com
Coloplast A/S - Interim Financial Report, Q1 2023/24
February 9, 2024 | finance.yahoo.com
Coloplast launches Peristeen® Light for people with bowel disorders
February 7, 2024 | morningstar.com
Coloplast A/S ADR
January 31, 2024 | finance.yahoo.com
Coloplast launches Biatain® Silicone Fit for pressure injury prevention and wound management in the US
December 7, 2023 | msn.com
Coloplast A/S goes ex-dividend tomorrow
November 14, 2023 | finance.yahoo.com
Coloplast A/S - Notice of Annual General Meeting 2023
November 9, 2023 | finance.yahoo.com
Coloplast A/S: Coloplast Earnings: Revenue Growth Remains Solid, but Margin Drag Likely to Last Into 2024
September 1, 2023 | finance.yahoo.com
Coloplast A/S - Announcement no. 08/2023 - Coloplast announces registration of share capital increase of 12.2 new B shares completed
August 18, 2023 | finance.yahoo.com
Major shareholder notification
August 17, 2023 | finance.yahoo.com
Coloplast A/S - Announcement no. 04/2023 - Interim Financial Report, 9M 2022/2023
July 7, 2023 | finance.yahoo.com
Coloplast A/S - Announcement no. 03/2023 - Coloplast announces agreement to acquire Kerecis and raises long-term growth expectations
May 19, 2023 | seekingalpha.com
CLPBY Coloplast A/S
May 13, 2023 | msn.com
Coloplast AS - Class B (CLPBF) Declares $5.00 Dividend
May 11, 2023 | finance.yahoo.com
Coloplast A/S - Announcement no. 02/2023 - Interim Financial Report, H1 2022/23
May 7, 2023 | cbsnews.com
Sam's Club May 2023 membership deal: Get one year of discounted gas, food and more for $35
April 24, 2023 | finance.yahoo.com
New clinical study demonstrates significant improvement in pulmonary health and related symptoms when using Provox® Life™
April 5, 2023 | benzinga.com
Short Volatility Alert: Coloplast
March 28, 2023 | cbsnews.com
Sam's Club March membership deal: Get one year of discounted gas, groceries and more for $25
See More Headlines
Receive CLPBY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Coloplast A/S and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/09/2024
Today
4/18/2024
Fiscal Year End
9/30/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Surgical appliances & supplies
Sub-Industry
N/A
Current Symbol
OTCMKTS:CLPBY
Previous Symbol
NASDAQ:CLPBY
CUSIP
N/A
CIK
1294325
Web
www.coloplast.com
Phone
(454) 911-1111
Fax
N/A
Employees
15,913
Year Founded
1954

Profitability

EPS (Most Recent Fiscal Year)
$0.33
Trailing P/E Ratio
39.27
Forward P/E Ratio
37.03
P/E Growth
3.07
Net Income
$685.88 million
Net Margins
19.48%
Pretax Margin
24.59%
Return on Equity
43.30%
Return on Assets
11.89%

Debt

Debt-to-Equity Ratio
0.76
Current Ratio
0.53
Quick Ratio
0.35

Sales & Book Value

Annual Sales
$3.58 billion
Price / Sales
N/A
Cash Flow
$0.43 per share
Price / Cash Flow
30.43
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
-0.04

Social Links

7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Kristian Villumsen (Age 54)
    President & CEO
    Comp: $2.55M
  • Mr. Anders Lonning-Skovgaard (Age 52)
    Executive VP & CFO
    Comp: $1.31M
  • Mr. Allan Rasmussen (Age 57)
    Executive Vice President of Global Operations
    Comp: $1.15M
  • Mr. Nicolai Buhl Andersen (Age 55)
    Executive Vice President of Innovation
    Comp: $1.11M
  • Mr. Paul Marcun (Age 57)
    Executive Vice President of Growth
    Comp: $1.33M
  • Mr. Thomas Barfod (Age 54)
    Senior Controller & Employees Representative Director
    Comp: $65.68k
  • Ellen Bjurgert
    Vice President of Investor Relations
  • Dennis Kaysen
    Director of Corporate Communications
  • Dorthe Ronnau (Age 58)
    Senior Vice President of People & Culture
  • Mr. Alain Morvan
    Senior Vice President of Sales Europe

Key Competitors

View All Competitors

Should I Buy Coloplast A/S Stock? CLPBY Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Coloplast A/S:

  • Coloplast A/S engages in the development and sale of intimate healthcare products and services globally, providing a diversified revenue stream.
  • The company offers innovative products like SenSura Mio and SpeediCath catheters, catering to a growing market for healthcare solutions.
  • Coloplast A/S operates in various segments including Chronic Care, Continence Care, and Advanced Wound Care, showcasing a broad product portfolio.
  • Recent financial reports indicate strong performance, with revenue growth and profitability, making it an attractive investment option.
  • The current stock price of Coloplast A/S reflects positive market sentiment and potential for future growth.

Cons

Investors should be bearish about investing in Coloplast A/S for these reasons:

  • Market competition in the healthcare sector could impact Coloplast A/S's market share and pricing power.
  • Regulatory changes or challenges in different regions may affect the company's operations and profitability.
  • Fluctuations in currency exchange rates could pose risks to Coloplast A/S's international business operations.
  • Economic uncertainties or global events could impact consumer demand for healthcare products, affecting the company's sales.
  • Investors should carefully monitor industry trends and company performance to make informed investment decisions.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, April 11, 2024. Please send any questions or comments about these Coloplast A/S pros and cons to contact@marketbeat.com.

CLPBY Stock Analysis - Frequently Asked Questions

Should I buy or sell Coloplast A/S stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Coloplast A/S in the last year. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" CLPBY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CLPBY, but not buy additional shares or sell existing shares.
View CLPBY analyst ratings or view top-rated stocks.

How have CLPBY shares performed in 2024?

Coloplast A/S's stock was trading at $11.53 at the beginning of the year. Since then, CLPBY shares have increased by 12.4% and is now trading at $12.96.
View the best growth stocks for 2024 here.

Are investors shorting Coloplast A/S?

Coloplast A/S saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 7,900 shares, an increase of 203.8% from the March 15th total of 2,600 shares. Based on an average daily trading volume, of 129,900 shares, the short-interest ratio is presently 0.1 days.
View Coloplast A/S's Short Interest.

How were Coloplast A/S's earnings last quarter?

Coloplast A/S (OTCMKTS:CLPBY) issued its quarterly earnings results on Friday, February, 9th. The company reported $0.08 earnings per share for the quarter, meeting analysts' consensus estimates of $0.08. The firm earned $953.60 million during the quarter. Coloplast A/S had a trailing twelve-month return on equity of 43.30% and a net margin of 19.48%.

How often does Coloplast A/S pay dividends? What is the dividend yield for Coloplast A/S?

Coloplast A/S declared a dividend on Friday, November 17th. Investors of record on Monday, December 11th will be given a dividend of $0.1498 per share on Friday, December 22nd. The ex-dividend date is Friday, December 8th. This is an increase from the stock's previous dividend of $0.05.
Read our dividend analysis for CLPBY.

How do I buy shares of Coloplast A/S?

Shares of CLPBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:CLPBY) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!
Priority Gold
[Urgent!] Generational Wealth Gameplan
Crypto 101 Media
Emergency: Biden's $20 Trillion Mistake Could Cost YOU!
GoldenCrest Metals
Biden’s $374B Giveaway Into This Sector
DTI
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research
He Is Giving Away Bitcoin
Crypto Swap Profits